EGFR and lung carcinoma: In lung cancer, evidence of prognostic and predictive value is available for monitoring of the human epidermal growth factor receptor T790M (EGFR T790M) resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI) [26], as reflected by the FDA approval for the Cobas EGFR mutation test in 2016 [18].